Core binding factor acute myelogenous leukaemia (CBF-AML), comprising up to 12–15% of all AML cases35 characterised by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16), is considered good-risk AML in the context of cytarabine based intensive chemotherapy36. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.